Evidence map›Paper›PMID 26149229›Full record

ArticleNeuroscience letters2015

Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke.

Yinghua Jiang, Xiang Fan, Zhanyang Yu, Chongjie Cheng, Xiao-Shu Wang, Eng H Lo, Xiaochuan Sun, Xiaoying Wang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Yinghua JiangDepartment of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China; Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School. Boston, MA, USA.
Xiang FanResearch Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School. Boston, MA, USA.
Zhanyang YuNeuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School. Boston, MA, USA.
Chongjie ChengDepartment of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China; Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School. Boston, MA, USA.
Xiao-Shu WangDepartment of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China; Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School. Boston, MA, USA.
Eng H LoNeuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School. Boston, MA, USA.
Xiaochuan SunDepartment of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Xiaoying WangDepartment of Neurosurgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China; Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School. Boston, MA, USA. Electronic address: wangxi@helix.mgh.harvard.edu.
Harvard University Press · USHarvard University · USFirst Affiliated Hospital of Chongqing Medical University · CNMassachusetts General Hospital · USTianjin University of Traditional Chinese Medicine · CN

Funding

Development of annexin A2 plus tPA as a novel stroke thrombolytic therapyU01NS072324 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XIAOYING · 2011 to 2014
$2.2M
Recombinant annexin A2 plus tPA for combination stroke therapyR01NS065998 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XIAOYING · 2010 to 2014
$1.9M
NINDS NIH HHS R01 NS065998NINDS NIH HHS R01-NS065998NINDS NIH HHS U01 NS072324NINDS NIH HHS U01-NS072324
6 · The paper itself

Abstract

We previously have shown that tissue type plasminogen activator (tPA) in combination with its receptor annexin A2 (rA2) protein significantly improved tPA thrombolytic efficacy. In this study we aimed to examine the therapeutic effects of the combination when treated at delayed 4-hour window after stroke compared to standard conventional tPA alone in an embolic focal stroke rat model. We compared effects of intravenous tPA alone (10 mg/kg) versus a combination of low-dose tPA (5 mg/kg) plus 10 mg/kg rA2. Totally 152 rats were used. Our results showed that: (1) at 24 h after stroke, the combination slightly reduced brain infarction compared to saline (9.2% reduction), and tPA (7.4% reduction), although the reductions did not reach statistical significance; while the combination significantly reduced (22.2% reduction) the conventional tPA-elevated intracerebral hemorrhagic (ICH) transformation; (2) at 7 days after stroke, the combination significantly attenuated conventional tPA alone-elevated iron deposition at peri-lesion area (68.2% reduction); (3) at 28 days after stroke, the combination significantly improved performance of adhesive tape-removal test, which was accompanied by a significantly higher micro vessel density at peri- infarct areas compared to conventional tPA alone group.In conclusion, compared to conventional tPA alone, when treated at delayed 4-hour after stroke, the combination of low-dose tPA plus rA2 therapy provides a safer profile by lowering risk of ICH transformation and improves neurological function recovery after stroke.

Indexed as

AnimalsAnnexin A2BrainBrain InfarctionCerebral HemorrhageDrug Therapy, CombinationIntracranial EmbolismMaleRats, WistarStrokeTime FactorsTissue Plasminogen ActivatorAnnexin A2Tissue Plasminogen ActivatorAnnexin A2Combination thrombolytic therapyEmbolic focal strokeIntracerebral hemorrhagic transformationLong term neurological outcomesTissue plasminogen activator

Identifiers

PMID26149229
PMCPMC4739853
OpenAlexW946123018

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.